Figure 5. . Treatments received by commercial and Medicare patients from index to first myasthenia gravis exacerbation and between exacerbations during 2-year follow-up.
‘Biologics’ includes rituximab and eculizumab.
AChEI: Acetylcholinesterase inhibitor; CS: Corticosteroid; IVIg: Intravenous immunoglobulin; NSIST: Non-steroidal immunosuppressive therapy; PLEX: Plasma exchange.